1 week Ago By Defense World Staff
American Century Companies Inc. grew its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 55.
2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 141,265 shares of the biopharmaceutical company’s stock after buying an additional 50,238 shares during the quarter. American Century Companies Inc.
owned approximately 0.08% of ACADIA Pharmaceuticals worth $2,592,000 as of its most recent filing with the Securities and Exchange Commission. Other hedge funds also recently modified their holdings of the company.
SG Americas Securities LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after acquiring an additional 1,966,607 shares in the last quarter.
Barclays PLC boosted its stake in ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after purchasing an additional 154,854 shares in the last quarter.
Burney Co. acquired a new position in ACADIA Pharmaceuticals in the fourth quarter worth $6,953,000. Proficio Capital Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $272,000.
Finally, State Street Corp increased its stake in shares of ACADIA Pharmaceuticals by 3.0% in the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock valued at $91,878,000 after buying an additional 173,084 shares in the last quarter.
Institutional investors and hedge funds own 96.71% of the company’s stock. ACADIA Pharmaceuticals Trading Down 5.
0 %Shares of ACADIA Pharmaceuticals stock opened at $14.61 on Tuesday. The stock’s fifty day simple moving average is $18.
06 and its 200 day simple moving average is $17.04. The company has a market capitalization of $2.
44 billion, a PE ratio of 18.73 and a beta of 0.54.
ACADIA Pharmaceuticals Inc. has a 12 month low of $14.15 and a 12 month high of $20.
68. Wall Street Analyst Weigh InSeveral research analysts recently issued reports on ACAD shares. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th.
They set a “hold” rating and a $22.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $28.
00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th.
StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Finally, Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $23.
00 to $20.00 in a research note on Friday, January 3rd. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock.
Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.93.
Read Our Latest Stock Analysis on ACADIA PharmaceuticalsInsiders Place Their BetsIn other news, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.
23, for a total transaction of $89,673.37. Following the completion of the sale, the director now owns 17,595 shares of the company’s stock, valued at $320,756.
85. This represents a 21.85 % decrease in their ownership of the stock.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 3,171 shares of the firm’s stock in a transaction on Wednesday, March 26th.
The stock was sold at an average price of $17.05, for a total transaction of $54,065.55.
Following the sale, the executive vice president now owns 56,889 shares in the company, valued at approximately $969,957.45. The trade was a 5.
28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,433 shares of company stock worth $187,319 over the last ninety days.
28.30% of the stock is currently owned by corporate insiders. ACADIA Pharmaceuticals Profile (Free Report)ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.Further ReadingFive stocks we like better than ACADIA PharmaceuticalsStock Analyst Ratings and Canadian Analyst RatingsOptions Activity Points to More Volatility for Palantir StockWhat is an Earnings Surprise? NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?What is Forex and How Does it Work? MicroStrategy Sees Insider Buy-Sell Action in Q1Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc.
(NASDAQ:ACAD – Free Report)..
